Ionis Pharmaceuticals Stock Investor Sentiment
| IONS Stock | USD 31.72 0.23 0.73% |
Slightly above 61% of Ionis Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Ionis Pharmaceuticals suggests that many traders are alarmed. Ionis Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Ionis Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Comfort Level 39
Alarmed
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ionis Pharmaceuticals' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ionis Pharmaceuticals.
News SentimentBullish | Hype SentimentNeutral | Insider SentimentDisposing |
Ionis Historical Sentiment
Although Ionis Pharmaceuticals' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Ionis, such as negative comments on social media and news outlets, may cause fear in the market and push Ionis Pharmaceuticals' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Ionis.
Ionis |
Ionis Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Ionis Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Ionis Pharmaceuticals Historical Investor Sentiment
Investor biases related to Ionis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Ionis. The trend in average sentiment can be used to explain how an investor holding Ionis can time the market purely based on public headlines and social activities around Ionis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ionis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ionis Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ionis Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Ionis Pharmaceuticals.
Far too much social signal, news, headlines, and media speculation about Ionis Pharmaceuticals that are available to investors today. That information is available publicly through Ionis media outlets and privately through word of mouth or via Ionis internal channels. However, regardless of the origin, that massive amount of Ionis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Ionis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Ionis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Ionis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Ionis Pharmaceuticals alpha.
Ionis Pharmaceuticals Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Baroldi Joseph of 2500 shares of Ionis Pharmaceuticals at 34.69 subject to Rule 16b-3 | 01/02/2025 |
2 | Acquisition by Bennett C Frank of 3607 shares of Ionis Pharmaceuticals subject to Rule 16b-3 | 01/30/2025 |
3 | Disposition of 1406 shares by Oneil Patrick R. of Ionis Pharmaceuticals at 32.4926 subject to Rule 16b-3 | 02/03/2025 |
4 | Ionis to hold fourth quarter and full year 2024 financial results webcast | 02/05/2025 |
5 | Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over 600 Million In 2025 Sales | 02/19/2025 |
6 | New positive donidalorsen data to be presented at AAAAIWAO Joint Congress highlight sustained HAE attack rate reduction and disease control | 02/20/2025 |
7 | Acquisition by Bennett C Frank of 320 shares of Ionis Pharmaceuticals at 28.2115 subject to Rule 16b-3 | 02/28/2025 |
8 | Disposition of 12295 shares by Devers Shannon L. of Ionis Pharmaceuticals subject to Rule 16b-3 | 03/03/2025 |
9 | Acquisition by Devers Shannon L. of 22000 shares of Ionis Pharmaceuticals at 34.69 subject to Rule 16b-3 | 03/04/2025 |
10 | Oligonucleotide Therapeutics Market Research 2025 Advancements in Genomics Accelerate Development of Targeted Oligonucleotide Drugs - Long-term Forecast to 2035 | 03/07/2025 |
11 | WAINZUA approved in the EU for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy | 03/10/2025 |
12 | Ono pays 280M to license Ionis rare disease drug | 03/12/2025 |
13 | Alnylam drug gets long-awaited FDA approval in deadly heart disease | 03/20/2025 |
14 | Are Troubling Developments Haunting Ionis Pharmaceuticals | 03/24/2025 |
15 | Ionis expands partnership with Sobi to include olezarsen commercialization outside the U.S. | 03/26/2025 |
Additional Tools for Ionis Stock Analysis
When running Ionis Pharmaceuticals' price analysis, check to measure Ionis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ionis Pharmaceuticals is operating at the current time. Most of Ionis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ionis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ionis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ionis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.